A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 May 2018
At a glance
- Drugs IDH 305 (Primary)
- Indications Acute myeloid leukaemia; Cancer; Glioma; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals Corporation
- 30 Apr 2018 Planned End Date changed from 26 Dec 2018 to 17 Apr 2019.
- 30 Apr 2018 Planned primary completion date changed from 2 Feb 2018 to 17 Apr 2019.
- 30 Apr 2018 Status changed from suspended to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History